You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Long-Term Disease Control in Moderate to Severe Atopic Dermatitis: Exploring the Potential of Biologic Therapies

  • Authors: Emma Guttman-Yassky, MD, PhD; Thomas Bieber, MD, PhD, MDRA; Melinda J. Gooderham, MSc, MD, FRCPC
  • CME / ABIM MOC Released: 8/9/2023
  • Valid for credit through: 8/9/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for dermatologists, allergists and clinical immunologists, primary care physicians, nurse practitioners, physician assistants, and other healthcare professionals involved in the care of patients with AD practicing globally.

The goal of this activity is for learners to be better able to recognize the unmet needs of patients with moderate to severe AD who continue to be treated inappropriately with topical or conventional systemic therapies, understand the differential mechanisms of action (MOAs) and key clinical data on emerging vs established biologics for moderate to severe AD, and to educate clinicians on the need for long-term disease control to improve outcomes and quality of life.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Differential mechanisms of action (MOAs) of biologic therapies for moderate to severe AD
    • Key clinical data for emerging biologics in moderate to severe AD
  • Have greater competence related to
    • Identifying key factors for the selection of an appropriate biologic treatment for a patient with moderate to severe AD
  • Demonstrate greater confidence in their ability to
    • Identify patients whose AD warrants treatment with systemic therapy


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Emma Guttman-Yassky, MD, PhD

    Waldman Professor of Dermatology and Immunology
    Health System Chair
    Department of Dermatology
    Icahn School of Medicine at Mount Sinai
    New York, New York, United States

    Disclosures

    Emma Guttman-Yassky, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Almirall; Amgen, Inc.; Aslan Pharmaceuticals; AstraZeneca; Biolojic Design; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Cara Therapeutics; Connect Pharma; DBV Technologies; Eli Lilly and Company; EMD Serono, Inc.; Evidera; Galderma Laboratories, L.P.; Gate Bio; Genentech; Incyte Corporation; Inmagene; Janssen Biotech; Kyowa Kirin Pharmaceutical Development, Inc.; Leo Pharma, Inc.; Merck; Pfizer, Inc.; Q32 Bio; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc.; Sanofi; SATO; Siolta; Target PharmaSolutions, Inc.; UCB; Ventyx
    Research funding from: Amgen, Inc.; AnaptysBio, Inc.; Aslan Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Cara Therapeutics; Concert Pharmaceuticals, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen; Kyowa Kirin Pharmaceutical Development, Inc.; Leo Pharma, Inc.; Pfizer, Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc.; Sanofi; UCB

  • Thomas Bieber, MD, PhD, MDRA

    Professor of Dermatology and Allergy
    University Hospital
    Bonn, Germany

    Disclosures

    Thomas Bieber, MD, PhD, MDRA, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Affibody; Allmiral; AnaptysBio, Inc. ; Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; Aslan Pharmaceuticals; Bayer HealthCare; BioVerSys; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Connect Pharma; Dermavant Sciences, Inc.; Domain Therapeutics; EQRx; Galderma Laboratories, L.P.; Glenmark; GlaxoSmithKline; Incyte Corporation; Innovaderm; IQVIA; Janssen; Kyowa Kirin Pharmaceutical Development, Inc.; Kymab; Leo Pharma, Inc.; LG Chem; L’Oreal; Merck Sharp & Dohme; Novartis; Numab; OM-Pharma; Pfizer, Inc.; Pierre Fabre; Q32bio; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc.; Sanofi; UCB
    Speaker or member of speakers bureau for: AbbVie, Inc.; Allmiral; Eli Lilly and Company; Galderma Laboratories, L.P.; Leo Pharma, Inc.; L’Oreal; Novartis; Pfizer, Inc.; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Sanofi; UCB

  • Melinda J. Gooderham, MSc, MD, FRCPC

    Medical Director
    SKiN Centre for Dermatology
    Assistant Professor
    Queens University
    Peterborough, Ontario, Canada

    Disclosures

    Melinda J. Gooderham, MSc, MD, FRCPC, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; Akros Pharma, Inc.; Amgen, Inc.; AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Asana BioSciences, LLC; Aslan Pharmaceuticals; Bausch Health Companies, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Galderma Laboratories, L.P.; Janssen Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; Leo Pharma, Inc.; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB
    Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Arcutis Biotherapeutics, Inc.; Aslan Pharmaceuticals; Bausch Health Companies, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Galderma Laboratories, L.P.; Janssen, Inc.; Leo Pharma, Inc.; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB
    Research funding from: AbbVie, Inc.; Akros Pharma, Inc.; Amgen, Inc.; AnaptysBio, Inc.; Arcutis Biotherapeutics, Inc.; Aristea Therapeutics; Aslan Pharmaceuticals; Bausch Health Companies, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Coherus Biosciences; Dermira Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; GlaxoSmithKline; Incyte Corporation; Janssen, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; Leo Pharma, Inc.; MedImmune Inc.; Merck & Co., Inc.; MoonLake Immunotherapeutics; Nimbus Therapeutics; Novartis Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries, Ltd.; UCB

Editor

  • Marinella Calle, PhD, CMPP

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Marinella Calle, PhD, CMPP, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Long-Term Disease Control in Moderate to Severe Atopic Dermatitis: Exploring the Potential of Biologic Therapies

Authors: Emma Guttman-Yassky, MD, PhD; Thomas Bieber, MD, PhD, MDRA; Melinda J. Gooderham, MSc, MD, FRCPCFaculty and Disclosures

CME / ABIM MOC Released: 8/9/2023

Valid for credit through: 8/9/2024, 11:59 PM EST

processing....

Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned. 

  • Print